Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
49 hedge funds and large institutions have $470M invested in Centessa Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 1 closing their positions.
1,086% more call options, than puts
Call options by funds: $166K | Put options by funds: $14K
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
9% more funds holding
Funds holding: 45 → 49 (+4)
8% more capital invested
Capital invested by funds: $435M → $470M (+$34.2M)
0.95% more ownership
Funds ownership: 73.57% → 74.51% (+0.95%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$14M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.97M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.21M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.27M |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$1.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$3.29M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$3.27M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$2.19M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.17M |
| 5 |
SCM
Sio Capital Management
New York
|
-$823K |
CNTA Hedge Fund Activity: Q3 2023 in Review
49 of the 6,312 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q3 2023, worth a combined $470M — up 7.8% from $435M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CNTA positions and 1 closed out — a net gain of 4 holders — while 17 added to existing stakes and 11 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $14M. The largest seller was Boxer Capital, cutting an estimated $3.29M.
- 49 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q3 2023, up from 45 in Q2 2023.
- Funds reported $470M of Centessa Pharmaceuticals stock for Q3 2023, up 7.8% quarter-over-quarter.
- 5 funds opened new Centessa Pharmaceuticals positions in Q3 2023 and 1 closed out, a net change of +4 holders.
- The largest Centessa Pharmaceuticals buyer in Q3 2023 was TCG Crossover Management, an estimated $14M added.
- The largest Centessa Pharmaceuticals seller in Q3 2023 was Boxer Capital, an estimated $3.29M sold.
Based on aggregated 13F filings for Q3 2023.